LA Analítica is the first digital platform focused on nuclear medicine data and analysis in Latin America and the Caribbean.
Our goal is to support the creation of local and regional strategies, in collaboration with public and private sectors, to expand equitable access to nuclear medicine.
This Landing Page is just a summary of what we aim for in the final version of the site: to offer data and analyses on access to diagnostic and treatment services, infrastructure, and regulation.
At LA Analítica, you'll find essential information on cyclotrons, reactors, nuclear medicine centers, scientific research, clinical trials, and key developments in Nuclear Medicine in Latin America, the Caribbean, and the world.
Mission
Identify obstacles hindering broad access to nuclear medicine methods. Produce analyses with public, private, and non-governmental sectors to raise awareness of these barriers and propose integrated solutions to promote equitable access.
Vision
At LA Analítica, we believe that by generating and sharing knowledge about the current state of nuclear medicine in Latin American and Caribbean countries, we can promote coordinated actions to minimize inequalities and improve equitable access to cutting-edge diagnostic and therapeutic technologies.
Values
- Equity: Equal access for all.
- Innovation: Advanced, creative solutions.
- Collaboration: Strategic partnerships.
- Transparency: Openness and accountability.
- Excellence: Quality in all actions.
- Sustainability: Long-lasting, local solutions.
Did you know that...
(as of 2023).
-
North21
-
North East67
-
Midwest48
-
Southeast253
-
South76
Lutetium-177-PSMA Radiopharmaceutical
Lutetium-177-PSMA, used to treat metastatic castration-resistant prostate cancer, was registered in the US in 2022, but has been used in Brazil since 2019 with special approval from ANVISA. In the US, only 2.1% of prostate cancer patients are treated with this therapy, while in Brazil, the figure is only 0.1%.
Latin America
Brazil performs the most PET-CT scans in Latin America, but countries like Uruguay and Chile have broader coverage of over 20 indications, compared to only 10 in Brazil.
PSMA
PSMA targets (18F-PSMA, 68Ga-PSMA) are primarily used in nuclear medicine diagnostics for prostate cancer but can also guide conventional treatment recommendations, such as pelvic radiation, lymph node therapy, and androgen deprivation therapy.
SUS and ANS
Most nuclear medicine procedures covered by the public healthcare system (SUS) in Brazil are performed in private centers, which are still reimbursed at rates set in 2009. The financial imbalance, due to the cost of imported equipment and inflation, negatively impacts nuclear medicine centers' management and patient care.